Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Protyon logo — Guiding clinicians towards personalized treatment and enhanc...

Protyon

Guiding clinicians towards personalized treatment and enhancing quality of life for patients

Founded 2022 The Netherlands The Netherlands 9 employees Seed Total: $601.50K AI, Biotechnology +3

General Information

Company Name Protyon
Founded Year 2022
Location The Netherlands The Netherlands
Employees 9
Industries AI, Biotechnology, Health Care +2
Funding Stage Seed
Business Model B2B, B2D, SaaS
Revenue Model Subscription, Service Fee, Licensing
Offices as of Oct 2026
Groningen, The Netherlands
Social

BounceWatch is an independent company data service, not affiliated with Protyon. To contact Protyon, visit protyon.tech.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Protyon compare?

A PDF of Protyon and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Protyon soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Oct 29, 2026

Protyon collaborates with Longkanker Nederland to ensure the best patient applications and international growth.

Market Expansion Oct 29, 2026

Protyon is expanding internationally into France with a presence at Gustave Roussy.

Protyon a competitor of yours? Have our desk watch it

About Protyon

Protyon, founded in 2022 and headquartered in The Netherlands, operates at the intersection of AI, Health Care, and Life Sciences. The company's mission is encapsulated in its slogan: "Guiding clinicians towards personalized treatment and enhancing quality of life for patients."

Protyon leverages molecular structures to optimize therapy selection, with an emphasis on genetic mutations such as EGFR in lung cancer. By collaborating with the Molecular Tumor Board at the UMCG and various patient organizations across Europe, Protyon stands out in the burgeoning field of personalized medicine.

In May 2023, the company secured a €600.00K seed investment led by LUMO labs and the NOM - Northern Netherlands Regional Development Agency. With its advanced focus on precision oncology, Protyon is poised as a promising contender for addressing critical needs in cancer treatment, offering substantial potential for growth and innovation.

Business keywords: Personalized Medicine, Molecular Analysis, EGFR Mutations, Lung Cancer Therapy, Protein Targeting, Oncology Research, Clinical Collaboration, Molecular Tumor Board, Patient-Centric Care, Cancer Biomarkers, Precision Oncology, Therapeutic Personalization, Mutation Analysis, Oncology Diagnostics

Services & Products

3D Digital Molecular Modeling
Therapeutic Effectiveness Prediction
Knowledge-based Medication Selection
Clinician Education Courses
Life Science Research Support

Target Customers

Clinicians Hospitals Oncologists Cancer Researchers Medical Professionals

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed €600.00K 2
LUMO labs
LUMO labs, NOM - Northern Netherlands Regional Development Agency
01 May 2023
Support Program $1.50K 1
University of Groningen
01 Jan 2022

Protyon Alternatives & Competitors

View All Alternatives
Protyon vs
Viewpoint Molecular Targeting, Inc.
Viewpoint Molecular Targeting, Inc. United States

Targeted α-Particle Radiotherapy for Cancer

Grant
10 employees
Biotechnology, Health Care
Protyon vs
Cvergenx
Cvergenx United States

An innovative leader in cancer molecular diagnostics, delivering personalized radiation therapy to e...

Seed
2 employees
Biotechnology, Health Care
Protyon vs
BioReperia
BioReperia Sweden

Accelerating drug discovery and predicting the best cancer treatment for you!

Series A
19 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Protyon

Guiding clinicians towards personalized treatment and enhancing quality of life for patients
Protyon was founded in 2022.
Protyon is headquartered in The Netherlands. As of Oct 2026, it also has offices in Groningen, The Netherlands.
Protyon operates in AI, Biotechnology, Health Care, Life Sciences and Pharmaceutical. Its work centres on Personalized Medicine, Molecular Analysis, EGFR Mutations and Lung Cancer Therapy. Its customers include Clinicians, Hospitals and Oncologists.
Protyon has a B2B, B2D and SaaS business model. Its revenue comes from Subscription, Service Fee and Licensing.
Protyon has approximately 9 employees.
Protyon has completed 2 funding rounds, raising a total of $601.50K. The latest funding stage is Seed.
Protyon offers: 3D Digital Molecular Modeling, Therapeutic Effectiveness Prediction, Knowledge-based Medication Selection, Clinician Education Courses, Life Science Research Support.
Top alternatives and competitors to Protyon include Viewpoint Molecular Targeting, Inc., Cvergenx, BioReperia, BoomRay Pharmaceuticals, Helomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Protyon and Viewpoint Molecular Targeting, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Protyon, https://www.bouncewatch.com/company/protyon, updated 12 October 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout